百利天恒收到与百时美施贵宝就iza-bren项目2.5亿美元里程碑付款

Core Insights - SystImmune, a wholly-owned subsidiary of Baillie Gifford, received a milestone payment of $250 million from Bristol-Myers Squibb, with the actual amount subject to bank fees [1] - The company has the potential to receive up to an additional $250 million in near-term or contingent payments, as well as up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1] - The milestone payments outlined in the collaboration agreement are contingent upon certain conditions, indicating uncertainty regarding the final amounts [1]